Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of <4.0 ng/mL

BJU International

Volumn 93, Issue 4, 2004, Pages 499-502

  Sokoloff, M H ^a,e   Yang, X J ^a,b,d   Fumo, M ^c   Mhoon, D ^a   Brendler, C B ^a  

^a Section of Urology   (United States)

^b Department of Pathology ^*  (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

Clinically significant; Immunohistochemistry; Prostate cancer; Prostatectomy; PSA

Indexed keywords

EOSIN; HEMATOXYLIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; FAMILY HISTORY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATECTOMY; STAINING; TUMOR VOLUME; URINARY DYSFUNCTION; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; TUMOR LOCALIZATION;

ADENOCARCINOMA; ADULT; AGED; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 1642311092     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2003.04657.x     Document Type: Article

References (23)

1. Canto EI, Shariat SF, Slawin KM. Biochemical staging of prostate cancer. Urol Clin North Am 2003; 30: 263-77
2. Fowler JE, Bigler SA, Farabaugh PB, Wilson SS. Prostate cancer detection in black and white men with abnormal digital rectal and prostate specific antigen less than 4 ng/ml. J Urol 2000; 164: 1961-3
3. Schroeder FH, van der Cruijsen-Koeter I, deKoning HJ et al. Prostate cancer detection at low prostate-specific antigen. J Urol 2000; 163: 806-9
4. Carvalhal GF, Smith DS, Mager DE et al. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less. J Urol 1999; 161: 835-9
5. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6-4 ng/ml and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA 1997; 277: 1452-5
6. Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal exam and serum prostate-specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6630 men. J Urol 1994; 151: 1283-90
7. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. New Eng J Med 2003; 349: 335-42
8. Schröder FH, Kranse R. Verification bias and the prostate-specific antigen test -is there a case for a lower threshold for biopsy? New Eng J Med 2003; 349: 393-5
9. Dugan JA, Bostwick DG, Myers RP et al. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996; 275: 288-94
10. Partin AW, Carter HB, Chan DW et al. Prostate-specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume, and benign hyperplasia. J Urol 1990; 143: 747-52
11. Tran TT, Sengupta A, Yang XJ. Prostatic foamy gland carcinoma with aggressive behavior: clinicopathological, immunohistochemical, and ultrastructural analysis. Am J Surg Pathol 2001; 25: 618-23
12. Chan TY, Chan DY, Stutzman KL, Epstein JI. Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors? J Urol 2001; 166: 2181-4
13. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-74
14. Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New Eng J Med 1991; 324: 1156-61
15. Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445-51
16. Partin AW, Yoo J, Carter HB et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110-4
17. Ronnett BM, Carmichael MJ, Carter HB, Epstein JI. Does prostatic epithelial neoplasia result in elevated serum prostate specific antigen levels? J Urol 1993; 150: 386-9
18. Genega EM, Hutchinson B, Reuter VE, Gaudin PB. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol 2000; 13: 1186-91
19. Weir EG, Partin AW, Epstein JI. Correlation of serum prostate specific antigen and quantitative immunohistochemistry. J Urol 2000; 163: 1739-42
20. Hirao Y, Ozono S, Kagebayashi Y, Yoshi M et al. The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Hinyokika Kiyo 1996; 42: 795-804
21. Noguchi M, Stamey TA, Neal JE, Yemoto CE. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. J Urol 2000; 163: 1751-5
22. Elgamal AA, Van de Voorde W, Van Poppel H et al. Exophytic papillary prostatic duct adenocarcinoma with endometrioid features, occurring in prostatic urethra after TURP. Urology 1994; 43: 737-42
23. Christensen WN, Steinberg G, Walsh PC, Epstein JI. Prostatic duct adenocarcinoma. Findings at radical prostatectomy. Cancer 1991; 67: 2118-24